When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Common cutaneous drug reactions

Última revisão: 12 Dec 2025
Última atualização: 22 Nov 2024

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • history of drug exposure
  • skin lesions
  • variable skin reactions within 5 to 15 minutes of drug exposure
  • variable skin reactions within a few hours of drug exposure
  • variable skin reactions within 2 weeks of drug exposure
  • variable skin reactions within months to years of drug exposure
  • previous exposure and reaction to drug
Detalhes completos

Outros fatores diagnósticos

  • pruritus
  • associated noncutaneous features
  • pain
Detalhes completos

Fatores de risco

  • virus infections
  • HIV infection
  • HLA-B*5701 polymorphism
  • HLA-B*1502 polymorphism
  • HLA-B*5801 polymorphism
  • female sex
Detalhes completos

Investigações diagnósticas

Tests to avoid

  • immunoglobulin G (IgG) allergy testing
Detalhes completos

Investigações a serem consideradas

  • blood (whole blood, plasma, serum) drug concentration
  • serum tryptase concentration (anaphylaxis)
  • complement pathway assay
  • histology of lesion biopsy
  • CBC and differential
  • antihistone antibodies to single-stranded DNA (lupus-like syndrome)
  • skin tests (prick tests, intradermal tests, patch tests)
  • drug-specific IgE
Detalhes completos

Novos exames

  • basophil activation test
  • lymphocyte proliferation assay (LPA/LTT)
  • enzyme-linked immunospot assay (ELISPOT test)

Algoritmo de tratamento

AGUDA

serious cutaneous adverse reactions

nonserious cutaneous adverse reactions

CONTÍNUA

following acute episode

Colaboradores

Autores

Michael Ardern-Jones, BSc, MBBS, DPhil, FRCP

Associate Professor

Consultant Dermatologist

Faculty of Medicine

University of Southampton

Southampton

UK

Declarações

MA-J declares that he has no competing interests.

Agradecimentos

Dr Michael Ardern-Jones would like to gratefully acknowledge Dr Wei Yann Haw, Dr Anne Holbrook, Dr Hermenio Lima, and Dr Jeffrey K. Aronson, the previous contributors to this topic.

Declarações

WYH, AH and HL declare that they have no competing interests. JKA is editor of Meyler's Side Effects of Drugs and its annual companion volumes, the Side Effects of Drugs Annuals.

Revisores

Shahbaz A. Janjua, MD

Specialist Dermatologist

Ayza Skin & Research Center

Lalamusa

Pakistan

Declarações

SAJ declares that he has no competing interests.

Craig K. Svensson, Pharm.D, PhD

Dean

College of Pharmacy, Nursing, and Health Sciences

Purdue University

West Lafayette

IN

Divulgaciones

CKS declares that he has no competing interests.

Agradecimiento de los revisores por pares

Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.

Divulgaciones

Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ. 2003 Nov 22;327(7425):1222-5. Resumen

Gell PG, Coombs RRA, eds. Clinical aspects of immunology. 1st ed. Oxford: Blackwell; 1963.

Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986 Dec 26;256(2):3358-63. Resumen

Kuokkanen K. Drug eruptions: a series of 464 cases in the Department of Dermatology, University of Turku, Finland, during 1966-1970. Acta Allergol. 1972 Dec;27(5):407-38. Resumen

Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28(10):851-70. Resumen

Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. 2022 Dec;150(6):1333-93.Texto completo  Resumen

Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239-45. Resumen

Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965 Jan;58(1):295-300.Texto completo  Resumen

Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med. 2009 May;102(5):186-94.Texto completo  Resumen

National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. September 2014 [internet publication].Texto completo

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
  • Common cutaneous drug reactions images
  • Differentials

    • Systemic lupus erythematosus
    • Autoimmune blistering disorders
    • Staphylococcal scalded skin syndrome
    Más Diferenciales
  • Guidelines

    • Anaphylaxis: a 2023 practice parameter update
    • Drug allergy: a 2022 practice parameter
    Más Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer